Pre-clinical evaluation of Rimeporide, an inhibitor of the sodium/proton exchanger type 1, for Duchenne muscular dystrophy, a fatal genetic disorder of chidhood onset

• Unité de recherche: INNOSUISSE
• Numéro de projet: 16065.1;5 PFLS-LS
• Titre du projet anglais: Pre-clinical evaluation of Rimeporide, an inhibitor of the sodium/proton exchanger type 1, for Duchenne muscular dystrophy, a fatal genetic disorder of chidhood onset

Description succincte (Anglais)

Pre-clinical evaluation of Rimeporide, an inhibitor of the sodium/proton exchanger type 1, for Duchenne muscular dystrophy, a fatal genetic disorder of chidhood onset

Description succincte (Français)

Pre-clinical evaluation of Rimeporide, an inhibitor of the sodium/proton exchanger type 1, for Duchenne muscular dystrophy, a fatal genetic disorder of chidhood onset

Résumé des résultats (Abstract) (Anglais)

EspeRare is a Swiss NPO skilled in drug development and program leadership for rare diseases. It is aiming at performing the pre-clinical validation of Rimeporide to treat Duchenne Muscular Dystrophy (DMD), a debilitating muscular disorder for which no cure exists. This project will generate data to obtain Orphan Designation and to initiate clinical trials. If successful, Rimeporide has an estimated peak sales of ca. 160M$/y by 2025. This project combines the expertise of EspeRare to the skills of UNIGE in pharmacotherapy and preclinical trials for DMD.

Résumé des résultats (Abstract) (Français)

EspeRare is a Swiss NPO skilled in drug development and program leadership for rare diseases. It is aiming at performing the pre-clinical validation of Rimeporide to treat Duchenne Muscular Dystrophy (DMD), a debilitating muscular disorder for which no cure exists. This project will generate data to obtain Orphan Designation and to initiate clinical trials. If successful, Rimeporide has an estimated peak sales of ca. 160M$/y by 2025. This project combines the expertise of EspeRare to the skills of UNIGE in pharmacotherapy and preclinical trials for DMD.